Previous close | 78.83 |
Open | 78.66 |
Bid | 79.33 x 800 |
Ask | 79.37 x 800 |
Day's range | 78.52 - 79.75 |
52-week range | 69.10 - 95.19 |
Volume | 1,089,597 |
Avg. volume | 3,135,783 |
Market cap | 40.549B |
Beta (5Y monthly) | 0.65 |
PE ratio (TTM) | 44.92 |
EPS (TTM) | 1.77 |
Earnings date | 04 Feb 2021 |
Forward dividend & yield | 0.98 (1.22%) |
Ex-dividend date | 03 Dec 2020 |
1y target est | 93.71 |
Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. and European markets.
Baxter BioPharma Solutions announced an agreement with Novavax to provide sterile manufacturing services for its COVID-19 vaccine candidate.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its fourth-quarter 2020 financial results on Thursday, February 4, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/5044187 to pre-register for the call and receive the call information.